Whole‑Body FDG‑PET/CT for Staging Suspected Lung Cancer

Detection of Occult Metastatic Disease

Whole‑body FDG‑PET/CT is the most sensitive imaging technique for identifying extracranial metastatic disease in lung cancer, with a sensitivity of ≈ 89 %【1 – American College of Radiology】.
In patients with locally advanced (stage III) or metastatic (stage IV) non‑small‑cell lung cancer, occult extrathoracic metastases are present in up to 37 % of cases【2 – American College of Radiology】.

Compared with CT alone, PET/CT improves overall staging accuracy and leads to management changes in 8–11 % of patients【3 – American College of Radiology】.
For bone metastases, FDG‑PET demonstrates sensitivity, specificity, accuracy, and negative predictive value > 90 %, outperforming bone scintigraphy【2 – American College of Radiology】.
For adrenal nodules, PET shows 94 % sensitivity and 82 % specificity; lack of FDG uptake reliably indicates a benign adenoma and eliminates the need for further work‑up【2 – American College of Radiology】.

The standard protocol mandates scanning from skull base to mid‑thigh to evaluate mediastinal and hilar nodes, liver, bone, and adrenal glands【3 – American College of Radiology】.
Hepatic metastases occur in 3–4 % of asymptomatic NSCLC patients at presentation, and PET/CT identifies hepatic lesions with 92–100 % accuracy【2 – American College of Radiology】.

Spiculated lesion margins are a classic morphologic sign that markedly increases the likelihood of malignancy【4 – American College of Radiology】.
Multiple lesions with irregular borders suggest multifocal primary disease or metastatic spread and therefore mandate comprehensive whole‑body staging【1 – Thoracic Oncology Society】.

FDG‑avid lymph nodes can be false‑positive due to infection or inflammation; tissue sampling is required when nodal uptake is the sole potential site of metastasis【2 – American College of Radiology】.
For optimal accuracy, PET/CT should be performed within 60 days of planned surgical resection and within 30 days before radiation therapy【2 – American College of Radiology】.

A limited chest‑only study would miss abdominal/pelvic metastases (liver, adrenal glands, peritoneum, distant lymph nodes)【2 – American College of Radiology】.
It would also fail to detect skeletal metastases throughout the axial and appendicular skeleton【2 – American College of Radiology】.
Whole‑body PET/CT can uncover unexpected additional primary malignancies, which a limited study would not reveal【1 – Thoracic Oncology Society】.

Order a whole‑body FDG‑PET/CT (skull base to mid‑thigh) for any patient with high‑risk lung lesions.
IV contrast is only necessary when a substantial mediastinal tumor component is present and vascular delineation is required【1 – Thoracic Oncology Society】.
Perform the scan before any biopsy or invasive intervention to avoid inflammatory changes that could confound interpretation【2 – American College of Radiology】.
If FDG‑avid adrenal nodules are the only site of possible metastasis, obtain biopsy confirmation【2 – American College of Radiology】.
Any FDG‑avid mediastinal lymph nodes identified on PET/CT should be sampled histologically, despite the high specificity of the modality【1 – Thoracic Oncology Society】.

Positive FDG‑PET/CT lymph nodes must be verified histologically when the result would alter the treatment plan – the American College of Radiology advises that any PET‑positive mediastinal or hilar node should be sampled because false‑positives can arise from infection or inflammation. 5
CT‑guided biopsy (or EBUS/TBNA) is required for solitary adrenal masses or single FDG‑avid mediastinal nodes in potentially resectable NSCLC – tissue confirmation is mandatory before abandoning curative surgery. 5
Pleural fluid cytology that is positive for malignant cells provides a definitive diagnosis without a separate tissue biopsy – this satisfies the need for histologic confirmation when pleural involvement is present. 5

Whole‑body FDG‑PET/CT (skull‑base to mid‑thigh) should be performed within 60 days of planned surgery for potentially resectable lung cancer – this comprehensive scan is the first step in the algorithm to identify metastatic sites. 5
Serial contrast‑enhanced chest CT every 3–6 months after curative treatment has a sensitivity of 93–94 % for detecting recurrent disease – regular imaging is recommended for early detection of recurrence. 5
When CT findings are equivocal, PET/CT is indicated, and any isolated PET‑positive site must be confirmed by tissue sampling – this ensures that PET‑only lesions are not misinterpreted as metastasis. 5

The negative predictive value of FDG‑PET/CT for mediastinal nodes is 83 %, which is lower than that of EBUS‑guided transbronchial needle aspiration (90 %) and mediastinoscopy (87 %). Consequently, histologic confirmation remains superior for nodal staging. 5